Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vesicular glutamate transporter 2 (VGLUT2), encoded by the SLC17A6 gene, is a transmembrane protein responsible for loading glutamate into synaptic vesicles in excitatory neurons [1]. In the spinal cord, VGLUT2 is the primary marker for excitatory interneurons in the dorsal horn, which play a pivotal role in the processing and transmission of nociceptive (pain) signals from the periphery to the brain [2]. These VGLUT2+ excitatory nociceptive interneurons are essential for both acute pain perception and the development of chronic pain states, such as mechanical allodynia and neuropathic pain [3, 4]. Research indicates that selective ablation or silencing of these neurons significantly reduces pain hypersensitivity, making them a high-interest target for analgesic development [2]. While direct pharmacological inhibition of VGLUT2 remains challenging due to its widespread expression in the central nervous system, including the thalamus and hypothalamus, cell-specific targeting strategies are being explored to modulate pain pathways without systemic toxicity [5]. Understanding the heterogeneity of VGLUT2+ subpopulations, such as those expressing somatostatin or calretinin, is crucial for developing more precise therapeutic interventions for chronic pain conditions [2]. Experimental inhibitors like Chicago Sky Blue 6B have been used to study VGLUT2 function, but clinical applications are currently limited by lack of selectivity [5].
Competitive inhibition of the vesicular glutamate transporter, preventing the loading of glutamate into synaptic vesicles and subsequently reducing the amount of glutamate released during exocytosis [1, 5].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vesicular glutamate transporter 2 (SLC17A6) (VGLUT2).